Combogesic

November 20, 2025

AFT delivers 10th consecutive first half revenue increase

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…

Read More

September 25, 2025

On track for $300m FY27 revenue; positive iron IV study result

– Sales tracking in line with $300 million FY27 revenue target – Clinical trial supports the potential patient benefits of novel iron IV development …

Read More

July 1, 2025

Combogesic IV launches in Canada; R&D progress

Q1 FY 26 HIGHLIGHTS – Maxigesic IV® (marketed as Combogesic IV®) launching in Canada this month and sales kick off for AFT Pharmaceuticals Canada a…

Read More